January 25, 2022: U.S. Patent No. 11,229,629 "Inhbitors of mitochondrial fission"

Queen’s Partnerships and Innovation is pleased to report the issuance of U.S. Patent No. 11,229,629 entitled, “Inhbitors of mitochondrial fission,” on January 25, 2022 to Danchen Wu, Michael Wells, and Stephen Archer. This patent relates to pharmaceutical compositions that include inhibitors of mitochondrial fission for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parkinsonism, Huntington’s Chorea, Alzheimer’s disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcoholic-related liver disease.

U.S. Patent No. 11,229,629 (PDF, 1.6 MB)